Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM756GE)

• Drug Name: APH-0812 Drug Info
• Synonyms: Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 2	[1]
Human immunodeficiency virus infection	1C62	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM756GE

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[3]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[5]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[10]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[11]

Drug(s) Targeting Protein kinase C (PRKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[12]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[14]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[15]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[16]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
SAFINGOL	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[17]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[18]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[19]
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]
Protein kinase C (PRKC)	TTYVX59	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [4] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [8] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [9] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [10] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [12] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [13] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [14] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [15] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [16] Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
• [17] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [18] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [19] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [20] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.